Anne Li March 25th, 2017
Denosumab (Xgeva) was non-inferior to zoledronic acid in delaying the time to skeletal-related events in patients with newly diagnosed multiple myeloma, according to a press release. To compare the efficacy of denosumab in delaying bone complications with that of zoledronic acid, the international, double-blind, phase 3 '482 study randomly assigned 1718 newly diagnosed patients with multiple myeloma to receive subcutaneous denosumab and intravenous placebo every 4 weeks, or intravenous zoledronic acid and subcutaneous placebo every 4 weeks.
See original article at: https://www.cancertherapyadvisor.com/multiple-myeloma/denosumab-delays-sres-in-multiple-myeloma/article/642155/